Literature DB >> 8350599

Clinicopathologic study of dextran sulfate sodium experimental murine colitis.

H S Cooper1, S N Murthy, R S Shah, D J Sedergran.   

Abstract

BACKGROUND: We undertook this study in order to fully characterize the clinical and histopathology features of the dextran sulfate sodium (DSS) model of experimental murine colitis and to discover the earliest histopathologic changes that lead to colitis. EXPERIMENTAL
DESIGN: Acute colitis was induced in Swiss-Webster mice by 7 days of oral DSS with animals sacrificed daily. Chronic colitis was induced by: (a) 7 days of oral DSS followed by 7 days of H2O (for 1, 2, and 3 cycles) and (b) 7 days of oral DSS followed by 14 and 21 days of H2O. In each experimental group, the entire colons were examined histologically and correlated with clinical symptoms.
RESULTS: Acute clinical symptoms (diarrhea and/or grossly bloody stool) were associated with the presence of erosions and inflammation. More importantly, the earliest histologic changes which predated clinical colitis was loss of the basal one-third of the crypt (day 3), which progressed with time to loss of the entire crypt resulting in erosions on day 5. The earliest changes were very focal and not associated with inflammation. Inflammation was a secondary phenomena and only became significant after erosions appeared. Animals treated with only 7 days of DSS followed by 14 and 21 days of H2O developed a chronic colitis with the following histologic features: areas of activity (erosions and inflammation), inactivity, crypt distortion, florid epithelial proliferation and possible dysplasia. These changes were similar to animals given 3 cycles of DSS. The clinical disease activity index correlated significantly with pathologic changes in both the acute and chronic phases of the disease.
CONCLUSIONS: The mechanism of DSS colitis is presently unknown. However, the finding of crypt loss without proceeding or accompanying inflammation suggests that the initial insult is at the level of the epithelial cell with inflammation being a secondary phenomena. This may be a good model to study how early mucosal changes lead to inflammation and the biology of the colonic enterocyte. Chronic colitis induced after only 7 days of DSS may serve as a useful model to study the effects of pharmacologic agents in human inflammatory disease and mechanisms of perpetuation of inflammation. Finally, we believe that this model has the potential to study the dysplasia cancer sequence in inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8350599

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  833 in total

Review 1.  Function of intestinal gammadelta T cells.

Authors:  R Boismenu
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  The SOS Response Mediates Sustained Colonization of the Mammalian Gut.

Authors:  Amanda N Samuels; Manuela Roggiani; Jun Zhu; Mark Goulian; Rahul M Kohli
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

3.  Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7.

Authors:  Naoki Matsumoto; Eriko Suzuki; Makoto Ishikawa; Takumi Shirafuji; Keiji Hasumi
Journal:  J Biol Chem       Date:  2014-10-31       Impact factor: 5.157

4.  Enteric neuronal density contributes to the severity of intestinal inflammation.

Authors:  Kara Gross Margolis; Korey Stevanovic; Nima Karamooz; Zi Shan Li; Ankur Ahuja; Fabien D'Autréaux; Virginia Saurman; Alcmene Chalazonitis; Michael David Gershon
Journal:  Gastroenterology       Date:  2011-04-28       Impact factor: 22.682

5.  Amelioration of dextran sulfate sodium-induced colitis by neuropeptide Y antisense oligodeoxynucleotide.

Authors:  Xue Hua Pang; Tian Ke Li; Qin Xie; Fu Qian He; De Jun Cui; You Qin Chen; Xiao Li Huang; Hua Tian Gan
Journal:  Int J Colorectal Dis       Date:  2010-06-05       Impact factor: 2.571

6.  VEGF-C mediated enhancement of lymphatic drainage reduces intestinal inflammation by regulating IL-9/IL-17 balance and improving gut microbiota in experimental chronic colitis.

Authors:  Xiaolei Wang; Jin Zhao; Li Qin
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

7.  Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer.

Authors:  Lauren C Chartier; Gordon S Howarth; Ian C Lawrance; Debbie Trinder; Scott J Barker; Suzanne Mashtoub
Journal:  Dig Dis Sci       Date:  2017-12-06       Impact factor: 3.199

8.  Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis.

Authors:  Pallavi Garg; Matam Vijay-Kumar; Lixin Wang; Andrew T Gewirtz; Didier Merlin; Shanthi V Sitaraman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-02       Impact factor: 4.052

9.  Bilirubin prevents acute DSS-induced colitis by inhibiting leukocyte infiltration and suppressing upregulation of inducible nitric oxide synthase.

Authors:  Stephen D Zucker; Megan E Vogel; Tammy L Kindel; Darcey L H Smith; Gila Idelman; Uri Avissar; Ganesh Kakarlapudi; Michelle E Masnovi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-09-17       Impact factor: 4.052

10.  GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa.

Authors:  Laia Egea; Christopher S McAllister; Omar Lakhdari; Ivelina Minev; Steve Shenouda; Martin F Kagnoff
Journal:  J Immunol       Date:  2013-01-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.